Press Room

News / Nov 11, 2019

Portugal’s Annual "St. Martin's Day" & 60th Anniversary Dinner

Hovione Macau organized the St. Martin's Day in our manufacturing facility in Macau

60th Anniversary Dinner Macau | Hovione

St. Martin's Day “ was held on 11th November, to commemorate the harvest of crops & the moment when the grapes become young wine. For many years, the Portuguese have celebrated the “St. Martin's Day “as a way of connecting all Portuguese around the world.

Since 2000, Hovione has been organizing this event to commemorate St. Martin's Day at Macau site’s garden. This year Hovione is also celebrating its 60th anniversary, the 40th anniversary of Hovione Hong Kong and the 35th anniversary of Hovione Macau.

To finalize we all toasted to Macau and to this wonderful celebration.

Portugal’s Annual "St. Martin's Day" & 60th Anniversary Dinner | Hovione

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026